January 5, 2005 -- Several biotechs made impressive gains during 2004, which bodes well for the sector in the year to come. The top gainers added well over 200% this year. In the US markets, Elan and NitroMed led the pack with gains close to 300%. Of the recent IPOs, Pharmion performed best with a gain of 175%, followed by Eyetech, which climbed nearly 120% for the year. Sector by sector, we dissect the best stocks and where the money seems to be flowing -- and where it’s not.
